Mylan N V (MYL) Gross Profit Margin starting from the third quarter 2020 to third quarter 2019, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Mylan N v   (NASDAQ: MYL)


Mylan N V 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MYL Gross Profit Margin (Sep 30 2020)
Q3 		(Jun 30 2020)
Q2 		(Mar 31 2020)
Q1 		(Dec 31 2019)
Q4 		(Sep 30 2019)
Q3
Y / Y Revenue Change 0.35 %
Seq. Revenue Change 8.82 %
Revenue In Millions $2,972.10
Gross Profit Margin 38.98 %
Gross Profit Margin Total Ranking # 2370
Gross Profit In Millions $1,158.50
Y / Y Gross Profit Change 8.03 %
Seq. Gross Profit Change 12.95 %


Commenting Third Quarter 2020 Gross Profit Margin
Mylan N v Gross Profit grew by 12.95 % in Q3 sequentially to 1,159 millions, while Revenue increased by 8.82 %, this led to improvement in the company's Gross Profit Margin to 38.98 %, Gross Profit Margin remained below Mylan N v average.


Observing third quarter 2020 results within Major Pharmaceutical Preparations industry 139 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 2269 to 2370.
Learn about Gross Margin
MYL's Gross Profit Margin third quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 140
Healthcare Sector # 406
Overall # 2309

Gross Profit Margin Statistics
High Average Low
56.94 % 42.97 % 30.82 %
(Dec. 31. 2003)   (Dec. 31. 2007)


MYL Gross Income Trends • More of MYL's Profitabilty Ratios • MYL Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
MYL's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
MYL's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for MYL's Competitors
Gross Profit Margin Profit Margin for Mylan N V 's Suppliers
Gross Profit Margin Profit Margin for MYL's Customers

You may also want to know
MYL's Annual Growth Rates MYL's Profitability Ratios MYL's Asset Turnover Ratio MYL's Dividend Growth
MYL's Roe MYL's Valuation Ratios MYL's Financial Strength Ratios MYL's Gross Profit Growth
MYL's Roa MYL's Inventory Turnover Ratio MYL's Growth Rates MYL's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2020, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2020 MRQ Gross ProfitSep 30 2020 MRQ Revenue
Vaccinex Inc   99.68 %$ 0.623  Millions$ 0.625  Millions
Deciphera Pharmaceuticals Inc   99.42 %$ 15.359  Millions$ 15.449  Millions
Rigel Pharmaceuticals Inc  99.24 %$ 18.249  Millions$ 18.389  Millions
Global Blood Therapeutics Inc.  98.61 %$ 36.376  Millions$ 36.889  Millions
Corcept Therapeutics Inc  98.59 %$ 85.111  Millions$ 86.327  Millions
Omeros Corporation  98.46 %$ 25.713  Millions$ 26.114  Millions
Acadia Pharmaceuticals Inc   98.34 %$ 118.572  Millions$ 120.577  Millions
Agios Pharmaceuticals Inc   98.16 %$ 34.068  Millions$ 34.706  Millions
Ionis Pharmaceuticals Inc   98.07 %$ 156.993  Millions$ 160.079  Millions
Nabriva Therapeutics Plc  98.06 %$ 1.266  Millions$ 1.291  Millions
Chiasma Inc   97.89 %$ 0.139  Millions$ 0.142  Millions
Intercept Pharmaceuticals inc   97.70 %$ 77.695  Millions$ 79.521  Millions
Travere Therapeutics Inc   97.67 %$ 49.950  Millions$ 51.139  Millions
Adamas Pharmaceuticals Inc  97.58 %$ 19.688  Millions$ 20.176  Millions
Ultragenyx Pharmaceutical Inc   97.12 %$ 79.122  Millions$ 81.470  Millions
Rvl Pharmaceuticals Plc  95.40 %$ 24.566  Millions$ 25.751  Millions
Zogenix Inc   95.10 %$ 2.720  Millions$ 2.860  Millions
Blueprint Medicines Corporation  94.99 %$ 708.916  Millions$ 746.291  Millions
Kyntra Bio Inc   94.99 %$ 41.825  Millions$ 44.032  Millions
Strongbridge Biopharma plc  94.94 %$ 7.663  Millions$ 8.071  Millions
Gw Pharmaceuticals Plc  94.43 %$ 129.418  Millions$ 137.053  Millions
Regeneron Pharmaceuticals Inc   94.29 %$ 2,163.000  Millions$ 2,294.000  Millions
Royalty Pharma Plc  93.72 %$ 504.607  Millions$ 538.399  Millions
United Therapeutics Corporation  93.69 %$ 356.100  Millions$ 380.100  Millions
Avalo Therapeutics Inc   93.10 %$ 1.034  Millions$ 1.111  Millions
Ocular Therapeutix Inc   92.34 %$ 5.426  Millions$ 5.876  Millions
Jazz Pharmaceuticals Plc  92.34 %$ 554.854  Millions$ 600.888  Millions
Emmaus Life Sciences Inc   91.36 %$ 5.117  Millions$ 5.601  Millions
Urogen Pharma Ltd   91.07 %$ 3.152  Millions$ 3.461  Millions
Sage Therapeutics Inc   90.91 %$ 1.490  Millions$ 1.639  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.